Tumor necrosis factor-alpha blockade with etanercept improves autonomic dysfunction in rheumatoid arthritis

Authors

  • Ashit Syngle Director Cardio Rheuma & Healing Touch City Clinic, Chandigarh & Senior Consultant Physician & Rheumatologist Fortis Multi Speciality Hospital, Mohali, India
  • Inderjeet Verma Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, India
  • Pawan Krishan Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, India
  • Simran Chahal Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, India
  • Vijaita Syngle Healing Touch City Clinic, Chandigarh

DOI:

https://doi.org/10.15305/ijrci/v4i1/198

Keywords:

Rheumatoid arthritis, etanercept, autonomic dysfunction, cardiovascular autonomic neuropathy, sudomotor dysfunction.

Abstract

Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease associated with autonomic neuropathy. There is no specific treatment recommendation for autonomic neuropathy (AN) in rheumatic diseases. In addition, there is no study demonstrating therapeutic efficacy of TNF-inhibitor (TNFi) etanercept on autonomic neuropathy in RA. This is the first reported observation of improvement in AN with blockade of TNFi-etanercept in RA. We report a case of a 46-year-old female with severe disease activity treated with subcutaneous etanercept 50mg once a week along with methotrexate 15 mg/week.  A significant improvement in cardiovascular autonomic neuropathy and sudomotor function was noted after 6 weeks of treatment.

 

References

Bennett PH, Scott JT. Autonomic neuropathy in rheumatoid arthritis: Ann Rheum Dis 1965;24:161-168.

Vinik AI, Nevoret ML, Casellini C. The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. Front. Endocrinol. 2015;6:94. doi: 10.3389/fendo.2015.00094.

Syngle A, Verma I, Krishan P, Garg N, Syngle V. Disease-modifying anti-rheumatic drugs improve autonomic neuropathy in arthritis: DIANA study. Clin Rheumatol. 2014.34:1233-41.

Syngle A, Verma I, Krishan P. Interleukin-6 blockade Improves Autonomic Dysfunction in Rheumatoid Arthritis. Acta Reumato Port. 2015; 40:85-8.

Syngle A, Verma I, Krishan P, Garg N. Tumor necrosis factor inhibition may improve autonomic dysfunction in rheumatoid arthritis. IJRCI. 2013; 1:CS7.

Boulton, AJ., Freeman, R., Vinik, AI. Diabetic neuropathies: a statement by the American diabetes association. Diabetes Care. 2005;28:956-962.

Milovanović B, Stojanović L, Milićevik N, Vasić K, Bjelaković B, Krotin M. Cardiac Autonomic Dysfunction in Patients with Systemic Lupus, Rheumatoid Arthritis and Sudden Death Risk. Srp Arh Celok Lek. 2010;138:26-32.

Syngle A, Verma I, Garg N, Krishan P. Mediators of Autonomic Neuropathy in Rheumatoid Arthritis. Annals of rheum dis. 2014;73 (Suppl2):633-34.

Sloan RP1, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study: Mol Med 2007;13:178-84.

Malave HA, Taylor AA, Nattama J, Deswal A, Mann DL. Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to moderate heart failure. Chest. 2003;123:716-24.

Holman, AJ. And Ng, E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. Auton Neurosci. 2008;143:58-67.

Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular disease. Psycho neuro endocrionology. 2008;33:1305-12

Downloads

Additional Files

Published

14-09-2016

Issue

Vol. 4 No. 1 (2016)

Section

Case Studies

License

Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.